The serum levels of hepatitis C virus (HCV) RNA represent the abundance of HCV production versus clearance and are usually stable in humans with untreated chronic hepatitis C (CHC) (1, 9, 12, 18, 22, 34, 39, 44, 49, 63) . Between individuals, however, these baseline HCV RNA concentrations ([HCV RNA] BL ) vary by 3 to 4 log 10 IU/ml and the factors that determine these differences are poorly understood.
To identify the determinants of interpersonal [HCV RNA] variability, one study examined [HCV RNA] among 969 individuals who acquired HCV through injection drug use (63) . Human immunodeficiency virus type 1 (HIV-1)-coinfected individuals had higher [HCV RNA] than those who were infected only with HCV; and among the latter group, a lower [HCV RNA] was independently associated with younger age, ongoing hepatitis B virus infection, and the absence of needle sharing. However, these factors explained only 8.5% of the person-to-person variability in [HCV RNA]. Similar results were observed in cohorts of 676 female injection drug users and 313 current and former drug users (59, 65) . These results may have been affected by HIV-1 coinfection, HCV reinfection, the biologic and analytic effects from the various HCV genotypes that infected these individuals, interassay variability of the assays used to quantify HCV RNA, or the absence of data for certain key factors or for very low [HCV RNA] (21, 59, 63, 65) .
In studies of alpha interferon-based therapy for CHC, [HCV RNA] BL have been predictive of a sustained virologic response (SVR) (16, 20, 24, 29, 36, 37, 41, 51, 72) . Another viral characteristic, the HCV genotype, has also been predictive of an SVR: genotype 1 (gt1), the most prevalent HCV type in the United States, was independently associated with a lower likelihood of achieving an SVR (9, 15, 16, 24, 37, 72) . Subsequently, patients with Ͼ2 ϫ 10 6 copies/ml of HCV gt1 RNA, which corresponds to 5.9 log 10 IU/ml, have been regarded to be less likely to achieve an SVR than those with lower baseline concentrations of HCV gt1 RNA or those with Ͼ5.9 log 10 IU/ml of gt2 or gt3 (16, 20, 24, 29, 36, 37, 41, 46-48, 51, 54, 72) . We recently identified 5.6 log 10 IU/ml as the [HCV RNA] BL that best discriminated a high (70%) from a low (43%) SVR for 568 gt1-infected patients who were treated for 48 weeks with 180 g/week of peginterferon ␣-2a and 1,000 to 1,200 mg/day of ribavirin (unpublished data). Another recent study associated baseline HCV quasispecies diversity and lymphoproliferative responses to HCV antigens with a lower SVR rate among patients with advanced fibrosis (42) . While these studies underscore the clinical importance of HCV RNA attributes, they also provide opportunities to identify correlations between [HCV RNA] BL and other baseline characteristics among the types of patients who are treated for CHC. Such correlations could be directly or indirectly predictive of an SVR.
Six recent clinical trials enrolled 3,985 HCV-infected patients to determine the safety and efficacy of peginterferon ␣-2a, with or without ribavirin, for CHC (16, 20, 24, 48, 54, 72) . Combined data from these studies, which had a wide range of [HCV RNA] BL and a high proportion of patients with gt1 infections, enabled us to study the interpersonal variability of [HCV RNA] among a large number of highly characterized patients who were infected with a prevalent and relatively treatment-resistant genotype. We therefore analyzed data from 2,472 HCV gt1-infected patients to determine if there were any correlations between [HCV RNA] BL and a variety of demographic, clinical, and other baseline characteristics.
MATERIALS AND METHODS
Patients. We retrospectively analyzed data from 2,472 HCV gt1-infected patients in six clinical trials of peginterferon ␣-2a, with or without ribavirin, for the treatment of CHC (16, 20, 24, 48, 54, 72) . These multicenter trials were conducted in Australia, Canada, Europe (including France, Germany, Greece, Spain, and Switzerland), Mexico, New Zealand, South America, Taiwan, and the United States. Each trial was approved by the ethics committee or review board for the institutions at which it was conducted. The patients' dates of HCV acquisition and CHC diagnosis were not known. When baseline data were collected, these patients had compensated CHC, without evidence of other chronic liver disease or infection with HIV-1, hepatitis A virus, or hepatitis B virus. They also had serum concentrations of alanine aminotransferase ([ALT]) higher than the upper limit of the reference range (ULRR) in the laboratory where testing was performed. Other inclusion and exclusion criteria are described in the trials' reports.
HCV RNA data. As reported previously (16, 20, 24, 48, 54, 72) , [HCV RNA] were determined as the numbers of copies/ml by use of the COBAS Amplicor HCV Monitor test (version 2.0; Roche Diagnostics, Branchburg, NJ). These studies determined the genotype and the subtype by phylogenetically analyzing the nucleotide sequence (6, 16, 24, 48, 54, 72) or the restriction fragment length polymorphism (17, 20) from amplified cDNA representing part of the HCV 5Ј nontranslated region. We converted HCV RNA concentrations to IU/ml by using the manufacturer-recommended factor of 2.7 copies/IU (46) and then logarithmically transformed these values before performing the analyses. . Because the 121 patients of African descent represented a small portion of the total (4.9%) and preliminary analyses did not identify any racially associated trends, we grouped these patients into the "other" category. We categorized a patient as cirrhotic if local histopathologic assessment, performed at the patient's treatment center, indicated cirrhosis or a transition to cirrhosis. We separately analyzed histologic activity index (HAI) scores (33) , which were determined at a central laboratory for 1,304 patients' liver tissues.
We designated categories for the analysis of age, weight and body mass index (BMI), and [ALT]. Our age cutoff of 40 years was previously associated with SVR (9, 16, 48, 72) . Like Zeuzem et al. (72) , we chose a weight of 85 kg to yield a category of relatively heavy patients: a weight of Ͼ85 kg and a height of Ͻ1.8 m correspond to one of our BMI categories, i.e., Ͼ 27 kg/m 2 . In three trials that yielded our data, the mean weight was similar to 85 kg or the mean BMI was close to 27 kg/m 2 (16, 24, 54) . Patients in our other BMI categories, 25 to 27 kg/m 2 and Ͼ30 kg/m 2 , are considered overweight and obese, respectively (www .nhlbi.nih.gov/guidelines/obesity/sum_evid.htm). As in four trials from which our data were derived (16, 20, 48, 72) , we categorized the mean baseline [ALT] relative to a value threefold higher than ULRR; i.e., Յ3ϫ ULRR and Ͼ3ϫ ULRR.
Analyses and statistical methods. We analyzed the patients' data according to sets of two or more [HCV RNA] BL groups or according to the continuum of the [HCV RNA] BL . One [HCV RNA] BL group of each set had an endpoint of 5.9 log 10 IU/ml, which has been considered the cutoff for the likelihood of SVR (16, 20, 24, 29, 36, 37, 41, 46-48, 51, 54, 72) . For sets of four or more [HCV RNA] BL groups (Tables 1 and 2) , we used the Cochran-Armitage linear trend test for proportions to determine if the percentage of patients in a category that represented another baseline characteristic (e.g., percent male) was increasing or decreasing as the HCV RNA concentration increased among the ordered [HCV RNA] BL groups. Similarly, we used regression analysis to test for differences between means in the HAI necrosis-inflammation score.
To test for associations between continuous [HCV RNA] BL values and other baseline characteristics, we used Pearson correlation analysis and analysis of variance. These analyses yielded R and R 2 coefficients and a probability value (P) from testing against the hypothesis of no association. Continuous variables yielded a Pearson correlation coefficient (R). Categorical variables yielded a coefficient of determination (R 2 ) by analysis of variance. An R 2 value ranges from 0 to 1 and is the proportion of the total [HCV RNA] BL variation that is explained by the other baseline characteristic. We performed multiple-regression analysis with all baseline characteristics that yielded P values of Ͻ0.1 for R values not 
RESULTS
Overall ranges and proportions of baseline characteristics. Among all 2,472 patients, [HCV RNA] BL were between 2.6 and 7.4 log 10 IU/ml. While the majority (55.1%) of these HCV RNA values were Ͼ6 log 10 IU/ml, 80.9% were between 5.25 and 7 log 10 IU/ml, and only 2.5% were Ͼ7 log 10 IU/ml (Fig. 1) . These patients were predominantly male, Caucasian, and more than 40 years old (for overall percentages, see the right-hand column of Table 1 and the bottom row of Table 2 ; for ranges, see Table 3 ). While 33.8% weighed more than 85 kg, 42.4% had BMIs of greater than 27 kg/m 2 . More than 45% were infected by parenteral exposure, and the numbers infected with HCV subtypes 1a and 1b, as determined from analysis of the 5Ј nontranslated region of cDNA, were nearly equal. Noting that elevated [ALT] was an inclusion criterion for the trials in which these patients were enrolled, 68.2% of the mean baseline [ALT] were more than threefold higher than the upper limit of the testing laboratory's reference range. [HCV RNA], with especially few points representing patients who weighed Ͻ61 kg or Ͼ86 kg and were Ͻ29 or Ͼ59 years old, respectively. These distributions are somewhat analogous to the two bars in Fig. 1 Tables 1 and 2 , we identified correlations with P values of Ͻ0.05 between increasing [HCV RNA] BL and higher percentages of patients who (i) were male, Ͼ40 years old, Ͼ85 kg in weight, or Ͼ27 kg/m 2 in BMI (Table 1) or (ii) had higher HAI scores for fibrosis or necrosis-inflammation (Table 2) . We identified similar trends (data not shown) when we analyzed the patients' data according to different [HCV RNA] BL groups, e.g., Յ5.0, Ͼ5.0 to Յ5.3, Ͼ5.3 to Յ5.6, and Ͼ5.9 log 10 IU/ml. All trends shown in Tables 1 and 2 also appeared when we reduced the number of [HCV RNA] BL groups to the two, Յ5.9 and Ͼ5.9 log IU/ml, that have been associated with SVR (16, 20, 24, 29, 36, 37, 41, 46-48, 51, 54, 72) . Among patients in another set of [HCV RNA] BL groups, those with Ͼ6.6 log 10 IU/ml appeared to be more likely than those with [HCV RNA] BL of Ͼ5.9 to Յ6.6 log 10 IU/ml to be Ͼ40 years old (69% and 64%, respectively) or gt1b-infected (53% and 48%, respectively) and less likely to weigh Ͼ85 kg (32% and 37%, respectively) or to have BMIs of Ͼ27 kg/m 2 (42% and 46%, respectively 2 ), HCV subtype, and HAI scores for fibrosis and for necrosis-inflammation (Table  3 ). The strength of each correlation was low; however, no individual factor explained more than 2.4% (R 2 ϭ 0.024) of the person-to-person differences in [HCV RNA] BL .
For certain subpopulations, linear regression analysis yielded correlations that were consistent with the observations pertaining to Fig. 2 (see above) and like those shown in Table 3 (Tables 1 to 3 and data not shown).
DISCUSSION
While the implications of [HCV RNA] BL for the treatment of CHC are well recognized, the reasons for differences between relatively stable [HCV RNA] among individuals with chronic HCV infection have remained obscure. We therefore analyzed the baseline data from 2,472 HCV gt1-infected patients in six trials of peginterferon ␣-2a, with or without ribavirin (16, 20, 24, 48, 54, 72) . We limited this study to HCV gt1 because it (i) infected 62% of the six trials' patients; (ii) is the most prevalent genotype in Australia, Europe, Japan, and the Western Hemisphere; and (iii) is relatively resistant to treatment (7, 9, 41, 71) . To our knowledge, our report also represents the largest number of patients who have been evaluated for determining the relationships between [HCV RNA] BL and other baseline characteristics.
By analyzing such characteristics according to [HCV RNA] BL groups, we identified correlations between increasing [HCV RNA] BL and male gender, age Ͼ40 years, a weight of Ͼ85 kg, a BMI of Ͼ27 kg/m 2 , or a higher HAI score for fibrosis or necrosis-inflammation. We obtained similar results, including those with P values of Ͻ0.05 for R not equal to 0, with HCV subtype 1b when we analyzed [HCV RNA] BL as a continuous variable. Multiple-regression analysis identified gender, age, BMI, and the fibrosis score as independent predictors of higher [HCV RNA] BL . Several of our findings are consistent with those presented in previous reports, e.g., higher [HCV RNA] among older persons (21, 63, 65) . Others determined that BMI and histopathologic changes were independent predictors of the response to interferon-based therapy (2) . While reports pertaining to correlations between [HCV RNA] and the extent of liver disease have been inconsistent (13, 14, 19, 23, 43, 49, 53, 64, 70) , at least one of our [HCV RNA] BL -HAI score associations appeared to be sample size dependent; i.e., regression of the [HCV RNA] BL and the fibrosis score yielded a P value of 0.0029 for 1,304 patients of all ages (Table 3) The most remarkable conclusion from these studies is that we do not understand a great deal about the determinants of [HCV RNA]. In our study, less than 5% of the interpersonal differences in the baseline HCV gt1 RNA concentration could be explained by the sociodemographic, HCV subtype, biochemical, and histopathologic characteristics that we analyzed. Other studies, which included HIV-1-coinfected individuals and characteristics such as the durations of HCV infection and drug use, explained Ͻ10% of the interpersonal variability in [HCV RNA] (21, 63, 65) . These results indicate that as yet unidentified biologic or analytic factors explain most of the person-to-person differences in [HCV RNA].
Several factors may have contributed to our low multipleregression R 2 values of 0.043 and 0.046. First, biologic variation and assay imprecision may have biased the [HCV RNA] BL that we analyzed. Imprecision may have been relatively high (due to the use of several testing laboratories, technologists, runs, and reagent lots), but the same well-characterized HCV RNA assay was used for all six trials. If these trials' HCV RNA testing yielded within-patient variability of approximately Ϯ0.5 log 10 IU/ml, as others have reported (1, 9, 12, 18, 22, 34, 39, 44, 49, 63) , such "noise" in single [HCV RNA] values would not have affected our analyses more they did than in earlier studies. (21) . Conversely, the HCV prevalence was Ϸ2.5-fold higher among those with diabetes than those without diabetes (40) . While pertinent data were not available for our study, most of the 2,472 patients were overweight or Ͼ40 years old (Table 1) , so it is likely that many were glucose intolerant or had diabetes.
Similarly, we did not have data for the genetic polymorphisms that undoubtedly were present among the patients whom we studied. Others have correlated certain polymorphisms with different states of HCV infection and associated disease; while they did not analyze [HCV RNA], their findings may provide clues to interpatient differences in [HCV RNA] BL . Several HCV manifestations, including the response to therapy, were associated with polymorphisms in genes that encode interferon-inducible enzymes (myxovirus resistance-1, oligoadenylate synthetase-1, and double-stranded-RNA-dependent protein kinase) or the low-density lipoprotein receptor (26, 32) . The two outcomes of acute HCV infection, clearance and persistence, correlated with different variants among class I and II alleles of the human leukocyte antigen major histocompatibility locus (60) (61) (62) 67) . HCV persistence was also linked, along with the response to therapy for CHC, to polymorphisms in genes that encode cytokines (tumor necrosis factor alpha, interleukin-10, and transforming growth factor-␤1), the chemokine receptor CCR5, and the CCR5 ligands RANTES and MCP-2 (10, 25, 26, 28, 31, 32, 50) . Finally, the progression of fibrosis and other HCV-associated histopathologic changes may be related to coagulation-cascade activity and hepatic accumulation of iron, which have been associated with mutations in factor V and hemochromatosis genes, respectively (27, 30, 57, 69) . It is intriguing to speculate that [HCV RNA] BL could be associated with such polymorphisms because most of these genes are involved in innate or acquired immunologic responses to infection and could therefore affect HCV replication.
Further research is needed to identify additional characteristics, including host genetic or environmental factors, that determine [HCV RNA] BL or that affect the pretreatment state of HCV infection. Findings from such research will contribute to a better understanding of the natural history of HCV infection and perhaps to the development of optimal therapy for CHC.
